Aerovate Therapeutics (AVTE) investor relations material

Executive summary

• Halted all development of AV-101 after negative Phase 2b results; no plans to resume R&D or develop new products.

• Entered into a merger agreement with Jade Biosciences; merger approved by shareholders and pending closing.

• Declared a special cash dividend of $69.6 million ($2.40/share) contingent on merger closing.

• Implemented a workforce reduction plan, terminating 92% of staff, incurring $6.5 million in one-time severance costs.

• Company will become a holding entity for Jade's business post-merger; Aerovate shareholders will own ~1.6% of the combined company.

Financial highlights

• Net loss for Q1 2025 was $2.5 million, a significant improvement from $23.2 million in Q1 2024.

• No revenue generated; all product development discontinued.

• Cash and cash equivalents plus short-term investments totaled $76.2 million as of March 31, 2025.

• Operating expenses dropped to $3.4 million in Q1 2025 from $24.6 million in Q1 2024, reflecting the wind-down of R&D.

• Net cash used in operating activities was $2.4 million in Q1 2025, down from $23.7 million in Q1 2024.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least 12 months while completing the merger.

• No plans to resume AV-101 or initiate new product development; future operations depend on merger outcome.

• If merger fails, board may pursue dissolution and liquidation, with cash available for distribution dependent on timing and liabilities.